论文部分内容阅读
目的:探讨替罗非班治疗急性非ST段抬高的心肌梗死的临床疗效和安全性。方法:回顾性分析2009年6月至2011年6月我院采用替罗非班治疗非ST段抬高型急性心肌梗死患者112例(观察组)的临床资料,并与同期常规治疗的112例(对照组)患者相比较,比较两组的治疗效果和不良反应。结果:观察组80.36%的患者梗死相关血管血流分级达到Ⅲ级,明显高于对照组(P<0.05),而两组并发症的发生率无统计学差异(P>0.05)。结论:替罗非班治疗急性非ST段抬高型心肌梗死的疗效确切。
Objective: To investigate the clinical efficacy and safety of tirofiban in the treatment of acute non-ST segment elevation myocardial infarction. Methods: The clinical data of 112 patients (observation group) treated with tirofiban in our hospital from June 2009 to June 2011 were retrospectively analyzed. The data of 112 patients with non-ST-elevation acute myocardial infarction (Control group) patients, compared the two groups of treatment and adverse reactions. Results: 80.36% of patients in the observation group had grade Ⅲ infarction-related vascular grading, which was significantly higher than that of the control group (P <0.05). There was no significant difference in the incidence of complications between the two groups (P> 0.05). Conclusion: Tirofiban in the treatment of acute non-ST-segment elevation myocardial infarction is effective.